New article in BioStock: CombiGene comments on recent progress

Interviews and presentations 2020 2021   2020   2019   2018   2017   2016   2015 CombiGene has recently raised more than SEK 25 million through two successful warrants, which were excercised at 98.4 percent. At the same time, CombiGene's two gene therapy projects...

read more

New article about CombiGene in Biostock

Interviews and presentations 2020 2021   2020   2019   2018   2017   2016   2015 Biostock summarizes the latest news from CombiGene and talks to CEO Jan Nilsson about the importance of the many milestones and the continued plan for the epilepsy project CG01....

read more

CombiGene Chairman Bert Junno interviewed in BioStock

Interviews and presentations 2020 2021   2020   2019   2018   2017   2016   2015 CombiGene's Chairman of the Board Bert Junno is interviewed about what attracted him to CombiGene, how he sees the company’s strategy and future and upcoming milestones. Read the...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook